Cargando…
Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
BACKGROUND: In lung cancer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor sensitizing mutations co-existing with rare minor EGFR mutations are known as compound mutations. These minor EGFR mutations can lead to acquired resistance after EGFR tyrosine kinase inhibitor treatment, s...
Autores principales: | Namba, Kei, Tomida, Shuta, Matsubara, Takehiro, Takahashi, Yuta, Kurihara, Eisuke, Ogoshi, Yusuke, Yoshioka, Takahiro, Takeda, Tatsuaki, Torigoe, Hidejiro, Sato, Hiroki, Shien, Kazuhiko, Yamamoto, Hiromasa, Soh, Junichi, Tsukuda, Kazunori, Toyooka, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390598/ https://www.ncbi.nlm.nih.gov/pubmed/30808329 http://dx.doi.org/10.1186/s12885-019-5374-1 |
Ejemplares similares
-
Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019) -
Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis
por: Takahashi, Yuta, et al.
Publicado: (2018) -
Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019) -
Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018) -
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)